Literature DB >> 28236979

Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibition.

Tri Le1, Joseph Sailors2, Dwight H Oliver3, Melissa Mayer4, Sharon Hoskin4, David E Gerber5.   

Abstract

Resistance to EGFR kinase inhibitors appears to be invariable in the treatment of non-small cell lung cancer. Several mechanisms have been described. Here, we report the first case of histologic transformation of EGFR mutant lung adenocarcinoma without prior exposure to EGFR inhibition.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma NSCLC; EGFR; Squamous NSCLC

Mesh：

Substances：

Year:  2017        PMID： 28236979      PMCID： PMC5330183          DOI： 10.1016/j.lungcan.2017.01.005

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  4 in total

1.  Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib.

Authors:  Shiro Fujita; Katsuhiro Masago; Nobuyuki Katakami; Yasushi Yatabe
Journal:  J Thorac Oncol       Date:  2016-01-02       Impact factor: 15.609

2.  Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition.

Authors:  Pavel A Levin; Melissa Mayer; Sharon Hoskin; Joseph Sailors; Dwight H Oliver; David E Gerber
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

3.  EGFR-Driven Behavior and Intrapatient T790M Mutation Heterogeneity of Non-Small-Cell Carcinoma With Squamous Histology.

Authors:  Paolo Graziano; Filippo de Marinis; Bruno Gori; Rita Gasbarra; Rita Migliorino; Stefano De Santis; Giuseppe Pelosi; Alvaro Leone
Journal:  J Clin Oncol       Date:  2014-04-21       Impact factor: 44.544

4.  Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Authors:  Lecia V Sequist; Belinda A Waltman; Dora Dias-Santagata; Subba Digumarthy; Alexa B Turke; Panos Fidias; Kristin Bergethon; Alice T Shaw; Scott Gettinger; Arjola K Cosper; Sara Akhavanfard; Rebecca S Heist; Jennifer Temel; James G Christensen; John C Wain; Thomas J Lynch; Kathy Vernovsky; Eugene J Mark; Michael Lanuti; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2011-03-23       Impact factor: 17.956
  4 in total
  9 in total

1.  Checkpoint inhibitors in metastatic epidermal growth factor receptor-mutated non-small cell lung cancer patients: where we treating the wrong cancer?

Authors:  Paul Zarogoulidis; Vasilis Papadopoulos; Elena Maragouli; George Papatsibas; Haidong Huang
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

2.  Histologic transformation of non-small-cell lung cancer in brain metastases.

Authors:  Meng Jiang; Xiaolong Zhu; Xiao Han; Haiyan Jing; Tao Han; Qiang Li; Xiao Ding
Journal:  Int J Clin Oncol       Date:  2018-11-16       Impact factor: 3.402

3.  Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors.

Authors:  Jongmin Sim; Hyunjin Kim; Jiyeon Hyeon; Yoon La Choi; Joungho Han
Journal:  J Korean Med Sci       Date:  2018-04-09       Impact factor: 2.153

4.  Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma.

Authors:  Taiki Hakozaki; Miyako Kitazono; Mikio Takamori; Takahiro Kiriu
Journal:  Intern Med       Date:  2020-02-26       Impact factor: 1.271

5.  Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib.

Authors:  Kejing Tang; Neng Jiang; Yukun Kuang; Qiong He; Shuhua Li; Jiping Luo; Wenting Jiang; Yangshan Chen; Yu Sun; Lili Chen; Yanyang Chen; Junfeng Zhu; Yongmei Cui; Han Wan; Zunfu Ke
Journal:  Thorac Cancer       Date:  2018-12-06       Impact factor: 3.500

6.  EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCARE®.

Authors:  Konstantinos Sapalidis; Paul Zarogoulidis; Dimitris Petridis; Christoforos Kosmidis; Barbara Fyntanidou; Kosmas Tsakiridis; Elena Maragouli; Aikaterini Amaniti; Dimitris Giannakidis; Charilaos Koulouris; Stylianos Mantalobas; Athanasios Katsaounis; Vyron Alexandrou; Georgios Koimtzis; Efstathios Pavlidis; Anastasios Barmpas; Theodora Tsiouda; Chrysanthi Sardeli; Zoi Aidoni; Haidong Huang; Qiang Li; Wolfgang Hohenforst-Schmidt; Isaak Kesisoglou
Journal:  J Cancer       Date:  2019-08-20       Impact factor: 4.207

Review 7.  Pathological transition as the arising mechanism for drug resistance in lung cancer.

Authors:  Yueqing Chen; Waiying Yvonne Tang; Xinyuan Tong; Hongbin Ji
Journal:  Cancer Commun (Lond)       Date:  2019-10-01

8.  Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report.

Authors:  Jing Liu; Lei Xia; Yuan Peng; Yu Sheng Huang; Zhen Zhou Yang
Journal:  Medicine (Baltimore)       Date:  2021-10-01       Impact factor: 1.889

Review 9.  [Mechanism of Histologic Transformation of Drive Gene Positive Lung Adenocarcinoma in Targeted Therapy and Treatment Strategy].

Authors:  Tongji Xie; Yan Li; Puyuan Xing
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-08-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.